C2N Diagnostics, a U.S. based firm, has introduced a new diagnostic blood test that detects Alzheimer's disease in patients. The test, which measures amyloid particles and proteins that increase the risk of the disease, is designed for those over 60 who have noticed cognitive problems.
Even though it has been approved for use in Europe, the U.S. Food and Drug Administration is yet to green light the test in America.
Several scientific authorities are encouraged at the prospect of the test, but still hesitate to celebrate it as effective.
"We're encouraged, we're interested, we're funding this work but we want to see results," said Eliezer Masliah, the head of neuroscience at the U.S. National Institute on Aging.
Masliah's warning to be "cautious about interpreting" the test results were echoed by Heather Snyder of the Alzheimer's Association.
"It's not quite clear how accurate or generalizable the results are," Snyder said, adding that she will not endorse the development until it has earned the FDA's approval and been evaluated in larger populations.